---
title: "研究警報：CFRA 維持對宏利金融股票的買入意見"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/286513249.md"
description: "CFRA 對宏利金融（Manulife Financial Corp.）維持買入評級，12 個月目標價為 57 加元。該公司報告 2026 年第一季度核心每股收益為 1.06 加元，超過去年的 0.99 加元，淨收入上升至 11.47 億加元。亞洲市場表現強勁，核心收益增長 22%。目前，股票以折扣價交易，收益率為 3.3%，表明其被低估"
datetime: "2026-05-15T05:25:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286513249.md)
  - [en](https://longbridge.com/en/news/286513249.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286513249.md)
---

# 研究警報：CFRA 維持對宏利金融股票的買入意見

01:25 AM EDT, 05/15/2026 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We keep our 12-month target price of CAD57, valuing MFC shares at 12.7x our 2026 core EPS estimate of CAD4.50 (lowered from CAD4.60) and at 11.6x our 2027 EPS estimate of CAD4.90 (lowered from CAD5.00), versus the stock's one-year average forward multiple of 11x and a peer average of 12x. MFC posted Q1 2026 core EPS of CAD1.06 vs. CAD0.99 prior year, compared with our CAD1.10 estimate and the CAD1.09 consensus view. Net income surged to CAD1.147B from CAD485M, due to lower market experience charges and underlying business growth. We are encouraged by these results, particularly Asia's standout performance, with core earnings up 22% to CAD820M, APE sales up 11%, and NBV up 15%, reinforcing the region as MFC's key growth engine. Currently trading at 10.5x our 2027 EPS estimate (a discount to peer and historical averages) and currently yielding 3.3%, we view the shares as undervalued.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

### 相關股票

- [00945.HK](https://longbridge.com/zh-HK/quote/00945.HK.md)
- [MFC.US](https://longbridge.com/zh-HK/quote/MFC.US.md)

## 相關資訊與研究

- [宏利金融首季核心盈利升 8%，新造業務價值升 7%](https://longbridge.com/zh-HK/news/286336883.md)
- [宏利金融-S 股東週年大會通過推選 13 名董事](https://longbridge.com/zh-HK/news/286482738.md)
- [宏利香港及澳門首季核心盈利按年增長 27% 至 125 億元](https://longbridge.com/zh-HK/news/286345005.md)
- [宏利夥 Guardant Health 為香港客户獨家安排使用多種癌症檢測](https://longbridge.com/zh-HK/news/287007062.md)
- [宏利金融-S 發佈一季度業績 核心盈利 18 億加元 同比增長 8%](https://longbridge.com/zh-HK/news/286356094.md)